Potent low toxicity inhibition of human melanogenesis by novel indole-containing octapeptides

Biochimica et Biophysica Acta - General Subjects

Volumn 1820, Issue 10, 2012, Pages 1481-1489

  Ubeid, Anan Abu ^a   Do, Sylvia ^b   Nye, Chris ^b   Hantash, Basil M ^a  

^a Elixir Institute of Regenerative Medicine   (United States)

^b SAN JOSE STATE UNIVERSITY   (United States)

Author keywords

Copper chelation; Hydroquinone; Melanogenesis; Molecular docking; Octapeptide; Tyrosinase inhibition

Indexed keywords

ARGINYLARGINYLARGINYLTYROSYLTRYPTOPHANYLTYROSYLTYROSYLARGININE; ARGINYLARGINYLPHENYLALANYLVALYLCYSTEINYLCYSTEINE; ARGINYLARGINYLPHENYLALANYLVALYLLEUCYLLEUCINE; ARGINYLARGINYLTRYPTOPHANYLTRYPTOPHANYLARGINYLARGINYLTYROSYLTYROSINE; ARGINYLARGINYLTYROSYLTRYPTOPHANYLTYROSYLTRYPTOPHANYLARGINYLARGININE; ARGINYLARGINYLVALYLALANYLLEUCINE; HYDROQUINONE; MELANIN; MONOPHENOL MONOOXYGENASE; OCTAPEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL TYPE; CELL VIABILITY; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; KERATINOCYTE; MELANOCYTE; MELANOGENESIS; MOLECULAR DOCKING; MUSHROOM; PRIORITY JOURNAL; SKIN FIBROBLAST;

AGARICALES; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERPIGMENTATION; INDOLES; INFANT; MELANINS; MELANOCYTES; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MONOPHENOL MONOOXYGENASE; OLIGOPEPTIDES; PROTEIN INTERACTION MAPPING; SKIN PIGMENTATION;

BASIDIOMYCOTA;

EID: 84863227455     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.05.003     Document Type: Article

References (45)

1. A. Huijser, A. Pezzella, and V. Sundstrom Functionality of epidermal melanin pigments: current knowledge on UV-dissipative mechanisms and research perspectives Phys. Chem. Chem. Phys. 13 2011 9119 9127
2. A.L. Kadekaro, R.J. Kavanagh, K. Wakamatsu, S. Ito, M.A. Pipitone, and Z.A. Abdel-Malek Cutaneous photobiology. The melanocyte vs. the sun: who will win the final round? Pigment Cell Res. 16 2003 434 447
3. 2+ Exp. Cell Res. 294 2004 60 67
4. S. Parvez, M. Kang, H.S. Chung, C. Cho, M.C. Hong, M.K. Shin, and H. Bae Survey and mechanism of skin depigmenting and lightening agents Phytother. Res. 20 2006 921 934
5. K.G. Strothkamp, R.L. Jolley, and H.S. Mason Quaternary structure of mushroom tyrosinase Biochem. Biophys. Res. Commun. 70 1976 519 524
6. C.J. Cooksey, P.J. Garratt, E.J. Land, S. Pavel, C.A. Ramsden, P.A. Riley, and N.P. Smit Evidence of the indirect formation of the catecholic intermediate substrate responsible for the autoactivation kinetics of tyrosinase J. Biol. Chem. 272 1997 26226 26235
7. K.U. Schallreuter Advances in melanocyte basic science research Dermatol. Clin. 25 2007 283 291 vii
8. S. Ito, and K. Wakamatsu Chemistry of mixed melanogenesis - pivotal roles of dopaquinone Photochem. Photobiol. 84 2008 582 592
9. J.D. Simon, D. Peles, K. Wakamatsu, and S. Ito Current challenges in understanding melanogenesis: bridging chemistry, biological control, morphology, and function Pigment Cell Melanoma Res. 22 2009 563 579
10. C.B. Lynde, J.N. Kraft, and C.W. Lynde Topical treatments for melasma and postinflammatory hyperpigmentation Skin Therapy Lett. 11 2006 1 6
11. F. Solano, S. Briganti, M. Picardo, and G. Ghanem Hypopigmenting agents: an updated review on biological, chemical and clinical aspects Pigment Cell Res. 19 2006 550 571
12. S. Ennes, R. Paschoalick, and M.M.D.A. Alchorne A double-blind, comparative, placebo-controlled study of the efficacy and tolerability of 4 hydroquinone as a depigmenting agent in melasma J. Dermatolog. Treat. 11 2000 173 179
13. P.G. Engasser Ochronosis caused by bleaching creams J. Am. Acad. Dermatol. 10 1984 1072 1073
14. A.A. Fisher Current contact news. Hydroquinone uses and abnormal reactions Cutis 31 1983 240 244 250
15. C. Romaguera, and F. Grimalt Leukoderma from hydroquinone Contact Dermatitis 12 1985 183
16. E.V. Curto, C. Kwong, H. Hermersdorfer, H. Glatt, C. Santis, V. Virador, V.J. Hearing Jr., and T.P. Dooley Inhibitors of mammalian melanocyte tyrosinase: in vitro comparisons of alkyl esters of gentisic acid with other putative inhibitors Biochem. Pharmacol. 57 1999 663 672
17. H. Zhou, J.K. Kepa, D. Siegel, S. Miura, Y. Hiraki, and D. Ross Benzene metabolite hydroquinone up-regulates chondromodulin-I and inhibits tube formation in human bone marrow endothelial cells Mol. Pharmacol. 76 2009 579 587
18. N. Fujimoto, H. Onodera, K. Mitsumori, T. Tamura, S. Maruyama, and A. Ito Changes in thyroid function during development of thyroid hyperplasia induced by kojic acid in F344 rats Carcinogenesis 20 1999 1567 1571
19. M. Schurink, W.J. van Berkel, H.J. Wichers, and C.G. Boeriu Novel peptides with tyrosinase inhibitory activity Peptides 28 2007 485 495
20. M. Ishikawa, I. Kawase, and F. Ishii Combination of amino acids reduces pigmentation in B16F0 melanoma cells Biol. Pharm. Bull. 30 2007 677 681
21. A. Abu Ubeid, L. Zhao, Y. Wang, and B.M. Hantash Short-sequence oligopeptides with inhibitory activity against mushroom and human tyrosinase J. Invest. Dermatol. 129 2009 2242 2249
22. Y. Matoba, T. Kumagai, A. Yamamoto, H. Yoshitsu, and M. Sugiyama Crystallographic evidence that the dinuclear copper center of tyrosinase is flexible during catalysis J. Biol. Chem. 281 2006 8981 8990
23. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility J. Comput. Chem. 30 2009 2785 2791
24. O. Trott, and A.J. Olson AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 31 2010 455 461
25. W.L. DeLano Unraveling hot spots in binding interfaces: progress and challenges Curr. Opin. Struct. Biol. 12 2002 14 20
26. N. Guex, and M.C. Peitsch SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling Electrophoresis 18 1997 2714 2723
27. Y. Wang, J. Xiao, T.O. Suzek, J. Zhang, J. Wang, and S.H. Bryant PubChem: a public information system for analyzing bioactivities of small molecules Nucleic Acids Res. 37 2009 W623 W633
28. A.W. Schuttelkopf, and D.M. van Aalten PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. D: Biol. Crystallogr. 60 2004 1355 1363
29. L.Z. Piao, H.R. Park, Y.K. Park, S.K. Lee, J.H. Park, and M.K. Park Mushroom tyrosinase inhibition activity of some chromones Chem. Pharm. Bull.(Tokyo) 50 2002 309 311
30. E. Neeley, G. Fritch, A. Fuller, J. Wolfe, J. Wright, and W. Flurkey Variations in IC(50) values with purity of mushroom tyrosinase Int. J. Mol. Sci. 10 2009 3811 3823
31. D. Burk, H. Lineweaver, and C.K. Horner The specific influence of acidity on the mechanism of nitrogen fixation by Azotobacter J. Bacteriol. 27 1934 325 340
32. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
33. T. Kushimoto, V. Basrur, J. Valencia, J. Matsunaga, W.D. Vieira, V.J. Ferrans, J. Muller, E. Appella, and V.J. Hearing A model for melanosome biogenesis based on the purification and analysis of early melanosomes Proc. Natl. Acad. Sci. U. S. A. 98 2001 10698 10703
34. S.H. Pomerantz The tyrosine hydroxylase activity of mammalian tyrosinase J. Biol. Chem. 241 1966 161 168
35. A. Flurkey, J. Cooksey, A. Reddy, K. Spoonmore, A. Rescigno, J. Inlow, and W.H. Flurkey Enzyme, protein, carbohydrate, and phenolic contaminants in commercial tyrosinase preparations: potential problems affecting tyrosinase activity and inhibition studies J. Agric. Food Chem. 56 2008 4760 4768
36. H. Decker, T. Schweikardt, D. Nillius, U. Salzbrunn, E. Jaenicke, and F. Tuczek Similar enzyme activation and catalysis in hemocyanins and tyrosinases Gene 398 2007 183 191
37. H. Decker, T. Schweikardt, and F. Tuczek The first crystal structure of tyrosinase: all questions answered? Angew. Chem. Int. Ed. Engl. 45 2006 4546 4550
38. K. Sugimoto, T. Nishimura, K. Nomura, and T. Kuriki Syntheses of arbutin-alpha-glycosides and a comparison of their inhibitory effects with those of alpha-arbutin and arbutin on human tyrosinase Chem. Pharm. Bull.(Tokyo) 51 2003 798 801
39. S.H. Pomerantz, and M.C. Warner 3,4-dihydroxy-L-phenylalanine as the tyrosinase cofactor. Occurrence in melanoma and binding constant J. Biol. Chem. 242 1967 5308 5314
40. A. Sanchez-Ferrer, J.N. Rodriguez-Lopez, F. Garcia-Canovas, and F. Garcia-Carmona Tyrosinase: a comprehensive review of its mechanism Biochim. Biophys. Acta 1247 1995 1 11
41. K.B. Penney, C.J. Smith, and J.C. Allen Depigmenting action of hydroquinone depends on disruption of fundamental cell processes J. Invest. Dermatol. 82 1984 308 310
42. V.J. Hearing, and T.M. Ekel Mammalian tyrosinase. A comparison of tyrosine hydroxylation and melanin formation Biochem. J. 157 1976 549 557
43. K.U. Schallreuter, S. Kothari, B. Chavan, and J.D. Spencer Regulation of melanogenesis - controversies and new concepts Exp. Dermatol. 17 2008 395 404
44. N. Wang, and D.N. Hebert Tyrosinase maturation through the mammalian secretory pathway: bringing color to life Pigment Cell Res. 19 2006 3 18
45. D. McGregor Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties Crit. Rev. Toxicol. 37 2007 887 914